Wong Ka-Ying, Wong Man-Sau, Liu Juewen
Department of Chemistry, Waterloo Institute for Nanotechnology, University of Waterloo, Waterloo, ON, N2L 3G1, Canada.
Centre for Eye and Vision Research (CEVR), 17 W Hong Kong Science Park, Hong Kong.
Adv Healthc Mater. 2025 Mar;14(8):e2401309. doi: 10.1002/adhm.202401309. Epub 2024 May 17.
Nanozymes, characterized by their nanoscale size and enzyme-like catalytic activities, exhibit diverse therapeutic potentials, including anti-oxidative, anti-inflammatory, anti-microbial, and anti-angiogenic effects. These properties make them highly valuable in nanomedicine, particularly ocular therapy, bypassing the need for systemic delivery. Nanozymes show significant promise in tackling multi-factored ocular diseases, particularly those influenced by oxidation and inflammation, like dry eye disease, and age-related macular degeneration. Their small size, coupled with their ease of modification and integration into soft materials, facilitates the effective penetration of ocular barriers, thereby enabling targeted or prolonged therapy within the eye. This review is dedicated to exploring ocular diseases that are intricately linked to oxidation and inflammation, shedding light on the role of nanozymes in managing these conditions. Additionally, recent studies elucidating advanced applications of nanozymes in ocular therapeutics, along with their integration with soft materials for disease management, are discussed. Finally, this review outlines directions for future investigations aimed at bridging the gap between nanozyme research and clinical applications.
纳米酶具有纳米级尺寸和类酶催化活性，展现出多种治疗潜力，包括抗氧化、抗炎、抗菌和抗血管生成作用。这些特性使其在纳米医学尤其是眼部治疗中具有极高价值，无需进行全身给药。纳米酶在应对多因素导致的眼部疾病方面具有显著前景，特别是那些受氧化和炎症影响的疾病，如干眼症和年龄相关性黄斑变性。它们的小尺寸，加上易于修饰并整合到软材料中，有助于有效穿透眼部屏障，从而在眼内实现靶向治疗或延长治疗时间。本综述致力于探索与氧化和炎症密切相关的眼部疾病，阐明纳米酶在管理这些病症中的作用。此外，还讨论了近期关于纳米酶在眼部治疗中的先进应用以及它们与用于疾病管理的软材料整合的研究。最后，本综述概述了未来研究方向，旨在弥合纳米酶研究与临床应用之间的差距。
